A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozol...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroji, Masuda, Norikazu, Ohno, Shinji, Rai, Yoshiaki, Sato, Yasuyuki, Ohsumi, Shozo, Hashigaki, Satoshi, Nishizawa, Yoshinori, Hiraoka, Masahiro, Morimoto, Tadaoki, Sasano, Hironobu, Saeki, Toshiaki, Noguchi, Shinzaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/
https://www.ncbi.nlm.nih.gov/pubmed/23715630
http://dx.doi.org/10.1007/s10549-013-2573-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/
https://www.ncbi.nlm.nih.gov/pubmed/23715630
http://dx.doi.org/10.1007/s10549-013-2573-3

Ejemplares similares